| Title | Letters of intent due | Announcement URL |
|---|---|---|
| Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01 Clinical Trial Optional) | 4/10/18 | RFA-DK-18-004 |
| Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D) (R01 Clinical Trial Required) | 3/26/18 and 11/6/18 | RFA-DK-17-024 |
| Clinical, Behavioral and Physiological Research Testing Current and Novel Closed Loop Systems (R01 Clinical Trial Required) | 3/26/18 and 11/6/18 | RFA-DK-17-023 |
| Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for Type 1 Diabetes Therapy (R01 Clinical Trial Optional) | 4/10/18 | RFA-DK-17-025 |
| The Characterization and Discovery of Novel Autoantigens and Epitopes in Type 1 Diabetes (R01 Clinical Trial Optional) | 3/26/18 and 11/6/18 | RFA-DK-17-031 |
| Elucidating the Effect of Glycemic Excursions on Patient Well-being and Cognitive Status in People with Type 1 Diabetes (T1D) (R01 Clinical Trial Optional) | 6/10/18 | RFA-DK-18-003 |
| Discovery of Early Type 1 Diabetes Disease Biomarkers in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed) | 4/10/18 | RFA-DK-17-021 |
| High-Resolution Exploration of the Human Islet Tissue Environment [HIRN Human Pancreas Analysis Consortium (HPAC)] (U01 Clinical Trial Not Allowed) | 4/10/18 | RFA-DK-17-022 |
| Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes (R01 Clinical Trial Required) | 6/10/18 | RFA-DK-17-028 |
| Incorporating Patient-Reported Outcomes into Clinical Care for Type 1 Diabetes (R01 Clinical Trial Required) | 6/10/18 | RFA-DK-17-027 |
| Immune System Engineering for Targeted Tolerance in Type 1 Diabetes (R01 Clinical Trial Not Allowed) | April 10, 2018 and November 6, 2018 | RFA-DK-17-020 |
| Funding for Collaborative Clinical Research in Type 1 Diabetes: Living Biobank (R01 Clinical Trial Optional) | 6/10/18 | RFA-DK-17-032 |
| Career Development Programs in Diabetes Research for Endocrinologists (K12 Clinical Trial Optional) | 3/26/18 and 11/6/18 | RFA-DK-17-026 |
| Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Type 1 Diabetes Research (U01 Clinical Trial Not Allowed) | 6/10/18 | RFA-DK-17-019 |
| Limited Competition for the Continuation of the Clinical Centers for The Environmental Determinants of Diabetes in the Young (TEDDY) Study (U01 Clinical Trial Not Allowed) | 3/26/18 | RFA-DK-17-511 |
| Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44-Clinical Trial Not Allowed) | 2/21/18 | RFA-DK-17-030 |
| Support for Small Business Innovation Research to Develop New Open and Closed-Loop Automated Technologies for Better Type 1 Diabetes Therapy and Monitoring (SBIR) (R43/R44-Clinical Trial Not Allowed) | 2/21/18 | RFA-DK-17-029 |
Filed Under: Funding Opportunities